Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Tango Therapeutics 2024年第一季度公认会计准则每股收益美元（0.35）未达到预期（0.31）美元，销售额为64.71亿美元，低于预期的666.9万美元
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $6.471 million which missed the analyst consensus estimate of $6.669 million by 2.98 percent. This is a 12.23 percent increase over sales of $5.766 million the same period last year.
Tango Therapeutics（纳斯达克股票代码：TNGX）公布的季度亏损为每股0.35美元，比分析师普遍预期的0.31美元（0.31美元）低12.9％。与去年同期每股亏损0.32美元（0.32美元）相比，下降了9.37％。该公司公布的季度销售额为647.1万美元，比分析师共识估计的666.9万美元低2.98％。这比去年同期的576.6万美元的销售额增长了12.23％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。